The EPO published patent EP3990626A1 for a chimeric antigen receptor featuring a 4-1BB costimulatory domain. The applicant is Eutilex Co., Ltd., a Korean biotechnology company. The patent covers CAR constructs with applications in cancer immunotherapy (A61P 35/00), specifically involving T-cell engineering with costimulatory signaling domains. IPC classifications span C07K 14/705, C07K 16/28, C12N 5/0783, and related therapeutic protein and cell therapy classifications.

This is a patent publication notice with no immediate compliance obligations. Competitors in the CAR-T or immunotherapy space should review the patent claims to assess potential freedom-to-operate concerns. Companies developing similar costimulatory domain constructs or CAR-T products for the designated European states should consider whether their technology falls within the scope of these claims. No protest or opposition period applies at this publication stage.